Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets \u201cin order to make them lower\u201d in the U.S., an apparent response to the Trump administration\u2019s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as part of that effort.<\/p>\n
The announcement is among the first moves by a major drugmaker to raise prices abroad in order to lower them in the U.S., in line with President Trump\u2019s agenda. But it\u2019s not clear if these actions would actually increase the amount of revenue that Lilly earns abroad, since governments and private providers that cover drugs often negotiate discounts off the list prices. Lilly did not immediately announce any new price reductions in the U.S.<\/p>\n
Lilly said it will increase the list price of Mounjaro, which it sells for both diabetes and obesity in the U.K., from \u00a3122 to \u00a3330 at the highest dose, or roughly from $165 to $447. (In the U.S., the list price for a month\u2019s supply of Lilly\u2019s weight loss drug, which it sells as Zepbound in the U.S., is about $1,000.)<\/p>\n","protected":false},"excerpt":{"rendered":"
Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets \u201cin order to make them lower\u201d in the U.S., an apparent response to the Trump administration\u2019s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as part of that effort.<\/p>\n
The announcement is among the first moves by a major drugmaker to raise prices abroad in order to lower them in the U.S., in line with President Trump\u2019s agenda. But it\u2019s not clear if these actions would actually increase the amount of revenue that Lilly earns abroad, since governments and private providers that cover drugs often negotiate discounts off the list prices. Lilly did not immediately announce any new price reductions in the U.S.<\/p>\n